Published in Drug Law Weekly, August 11th, 2009
License agreement for EHT Dx14, a novel breast cancer diagnostic assay
Completion of Phase I safety studies for EHT/AGN 0001
Expansion of neurological research activities to epilepsy
Strengthening of shareholders' equity Outlook for remainder of 2009 EHT 0202 top-line Phase IIa results to be disclosed on September 14, 2009
First product launch with EHT Dx21 expected in Q4 2009 Key figures
June 30, 2009 (million EUR)
June 30, 2008
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly